General Information of Drug Combination (ID: DCOZWBI)

Drug Combination Name
Taxol MK-4827
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs Taxol   DMUOT9V MK-4827   DMLYGH4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: HT144
Zero Interaction Potency (ZIP) Score: 4.46
Bliss Independence Score: 3.84
Loewe Additivity Score: 6.71
LHighest Single Agent (HSA) Score: 8.61

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Pancreatic cancer 2C10 Phase 3 [4]
Gastric adenocarcinoma 2B72 Phase 2 [5]
Ovarian cancer 2C73 Phase 2 [5]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [2]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of MK-4827
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 3 [6]
Breast cancer 2C60-2C65 Phase 2 [4]
Ewing sarcoma 2B52 Phase 1 [4]
MK-4827 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Modulator [7]
------------------------------------------------------------------------------------
MK-4827 Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [8]
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [9]
Beta-glucuronidase (GUSB) DEP54UE BGLR_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
MK-4827 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCZKYOP ES2 Investigative [11]
Breast and ovarian cancer syndrome DCWCOXW UWB1289 Investigative [12]
Breast and ovarian cancer syndrome DC87280 UWB1289+BRCA1 Investigative [12]
Breast carcinoma DCLGQ69 KPL1 Investigative [12]
Breast carcinoma DCDQW9D OCUBM Investigative [12]
Carcinoma DCI4NAJ OV90 Investigative [12]
Carcinoma DC7OV6C EFM192B Investigative [12]
Colon adenocarcinoma DCDF9YY LOVO Investigative [12]
Colon carcinoma DCXTNRG RKO Investigative [12]
Invasive ductal carcinoma DCYMBDC T-47D Investigative [12]
Rectal adenocarcinoma DCKBMZY SW837 Investigative [12]
Adenocarcinoma DC59LE0 NCIH1650 Investigative [1]
Adenocarcinoma DCXKUGN NCIH520 Investigative [1]
Adenocarcinoma DCMOP06 COLO320DM Investigative [1]
Adenocarcinoma DCCZUCO DLD1 Investigative [1]
Adenocarcinoma DCZ8K39 HT29 Investigative [1]
Adenocarcinoma DCWATTV SW-620 Investigative [1]
Large cell lung carcinoma DCFVW72 NCI-H460 Investigative [1]
Malignant melanoma DCDMG9B RPMI7951 Investigative [1]
Malignant melanoma DCJW27T SKMEL30 Investigative [1]
Mesothelioma DCX9FK0 MSTO Investigative [1]
Non small cell carcinoma DCATH9F SKMES1 Investigative [1]
Ovarian endometrioid adenocarcinoma DC1PCTG A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DCT41RY SK-OV-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT03602859) A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). U.S. National Institutes of Health.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
9 Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
10 Autophagy up-regulated by MEK/ERK promotes the repair of DNA damage caused by aflatoxin B1. Toxicol Mech Methods. 2022 Feb;32(2):87-96. doi: 10.1080/15376516.2021.1968985. Epub 2021 Aug 26.
11 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
12 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.